Please login to the form below
Keynote-024
This page shows the latest Keynote-024 news and features for those working in and with pharma, biotech and healthcare.
Sanofi, Regeneron’s Libtayo scores first-line NSCLC approval in the US
In recently published long-term data from the phase 3 KEYNOTE-024 trial, Keytruda reduced the risk of death by 38% versus chemotherapy at the five-year time point among NSCLC ... In addition, another advanced, PD-1-positive NSCLC monotherapy study of
Latest news
-
Keytruda doubles five-year survival rate in NSCLC
The long-term data, from the phase 3 KEYNOTE-024 trial, demonstrated that treatment with Keytruda led to a sustained survival benefit and durable responses, when compared to chemotherapy in
-
NICE lung cancer backing for Keytruda is biggest expansion yet
The main KEYNOTE-189 study which backed the approval of Keytruda plus chemotherapy in first-line NSCLC therapy in Europe found that the combination regimen reduced the risk of death by ... The decision came after a budget impact review which took into
-
Keytruda cleared for frontline lung cancer in England - but only after another pricing deal
NICE’s draft decision was based on MSD’s Keynote 024 study, which first produced overall survival (OS) data in June 2017. ... While the ruling will be welcomed by all sides, it is by no means speedy - NICE made today’s decision on the Keynote 024
-
ASCO data back up Merck & Co's dominance in lung cancer
The results of the KEYNOTE-042 trial, reported at ASCO over the weekend, showed that giving Keytruda (pembrolizumab) to previously-untreated NSCLC patients improved survival by four to eight months compared ... Crucially, the trial enrolled patients with
-
Merck pulls Keytruda filing in Europe, despite US approval
from the FDA in May, after it became clear that the regulator was not prepared to approve on the strength of the KeyNote-0241 trial. ... Keytruda was approved for first-line NSCLC in patients whose tumours express higher levels of PD-L1 on the strength
More from news
Approximately 1 fully matching, plus 12 partially matching documents found.
Latest from PMHub
-
How pembrolizumab will change the management of advanced lung cancer
The results of the Phase III KEYNOTE-024 trial of pembrolizumab for non-small cell lung cancer (NSCLC) were presented by VJOncology Editorial Board Member Dr Martin Reck of LungenClinic Grosshansdorf. ... The Phase III KEYNOTE-024 trial assessed
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- Europe’s cancer community publishes new report on transforming patient care
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- EU outlines measures to mitigate antibiotic shortage across Europe
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- AbbVie trial backs chemo-free Imbruvica combo regimen
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- EU to revise pharmaceuticals law amid antibiotic shortages
PMHub
IPG Health Medical Communications
We are the world's most celebrated and awarded Medical Communications agencies. We are 800 experts obsessed with combining science, creativity...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
